Media stories about Kindred Biosciences (NASDAQ:KIN) have trended positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Kindred Biosciences earned a media sentiment score of 0.25 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 45.2316815085514 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Shares of Kindred Biosciences (NASDAQ:KIN) traded down $0.05 during mid-day trading on Thursday, hitting $8.50. The stock had a trading volume of 40,500 shares, compared to its average volume of 69,364. Kindred Biosciences has a one year low of $5.00 and a one year high of $9.80. The firm has a market cap of $240.96, a PE ratio of -7.26 and a beta of 0.07.
Several equities analysts have recently issued reports on KIN shares. B. Riley reiterated a “buy” rating and set a $11.00 price target on shares of Kindred Biosciences in a research report on Monday, November 20th. HC Wainwright started coverage on Kindred Biosciences in a research report on Friday, November 17th. They set a “buy” rating and a $9.50 price target on the stock. Aegis reiterated a “buy” rating on shares of Kindred Biosciences in a research report on Friday, December 15th. ValuEngine upgraded Kindred Biosciences from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Finally, Zacks Investment Research upgraded Kindred Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, January 13th. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $9.63.
In other news, Director Raymond Townsend sold 6,419 shares of the firm’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $9.45, for a total transaction of $60,659.55. Following the completion of the sale, the director now directly owns 18,419 shares of the company’s stock, valued at approximately $174,059.55. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 19.10% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY NOTICE: “Kindred Biosciences (KIN) Receiving Positive News Coverage, Analysis Finds” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/02/22/kindred-biosciences-kin-receiving-positive-news-coverage-analysis-finds.html.
Kindred Biosciences Company Profile
Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products.
Receive News & Ratings for Kindred Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.